HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance.
作者信息
Pascut Devis, Pratama Muhammad Yogi, Tiribelli Claudio
机构信息
Fondazione Italiana Fegato - ONLUS, Liver Research Center, AREA Science Park, ss14, Km163.5, Basovizza, 34149 Trieste, Italy.
Universitas Hasanuddin, Faculty of Medicine, Makassar, 90245, Indonesia.
出版信息
Hepat Oncol. 2020 Jun 22;7(2):HEP21. doi: 10.2217/hep-2020-0010.
Abstract
摘要
相似文献
1
HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance.直接抗病毒药物治疗后肝细胞癌的发生：评估治疗后风险和监测的分子工具
Hepat Oncol. 2020 Jun 22;7(2):HEP21. doi: 10.2217/hep-2020-0010.
2
Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study.直接抗病毒治疗清除丙型肝炎病毒后肝细胞癌发生预测的简易评分系统：全香川县肝病研究组研究
Oncol Lett. 2020 Mar;19(3):2205-2212. doi: 10.3892/ol.2020.11341. Epub 2020 Jan 23.
3
Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.预测 HCV 感染 DAA 治疗后 HCC 的极早期发生。
Hepatol Int. 2018 Nov;12(6):523-530. doi: 10.1007/s12072-018-9895-5. Epub 2018 Sep 21.
4
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
5
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.在纳入监测项目的肝硬化患者中，直接抗病毒治疗 HCV 后肝细胞癌的发生率。
Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19.
6
Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals.血清微小RNA是直接作用抗病毒药物治疗后早期肝细胞癌检测的有前景的生物标志物。
Cancers (Basel). 2019 Nov 11;11(11):1773. doi: 10.3390/cancers11111773.
7
APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation.APASL HCV 指南：DAA 治愈的 HCV 患者应如何监测 HCC 发生和 HBV 再激活。
Hepatol Int. 2019 Nov;13(6):649-661. doi: 10.1007/s12072-019-09988-7. Epub 2019 Sep 20.
8
HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation.直接作用抗病毒药物清除 HCV 不会影响等待肝移植患者的 HCC 进展或移植后 HCC 复发。
Can J Gastroenterol Hepatol. 2019 Jan 17;2019:2509059. doi: 10.1155/2019/2509059. eCollection 2019.
9
AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.AGA 临床实践更新：口服直接作用抗病毒药物治疗慢性丙型肝炎感染与肝细胞癌的相互作用：专家综述。
Gastroenterology. 2019 Jun;156(8):2149-2157. doi: 10.1053/j.gastro.2019.02.046. Epub 2019 Mar 13.
10
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis.直接作用抗病毒治疗后丙型肝炎相关肝硬化发生的肝细胞癌微血管侵犯的影像学特征。
Eur Radiol. 2018 Feb;28(2):506-513. doi: 10.1007/s00330-017-5033-3. Epub 2017 Sep 11.
引用本文的文献
1
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?直接作用抗病毒药物治疗慢性丙型肝炎感染与肝细胞癌的发生/复发：这仍然重要吗？
Viruses. 2024 Dec 10;16(12):1899. doi: 10.3390/v16121899.
2
Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients.索磷布韦/维帕他韦类抗病毒药物在中国患者中根除丙型肝炎的有效性和安全性的真实世界研究。
J Virus Erad. 2024 Dec 3;10(4):100571. doi: 10.1016/j.jve.2024.100571. eCollection 2024 Dec.
3
Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment.病毒性肝炎与肝细胞癌：从分子途径到临床监测和抗病毒治疗的作用。
World J Gastroenterol. 2022 Jun 7;28(21):2251-2281. doi: 10.3748/wjg.v28.i21.2251.
4
Epithelial-Mesenchymal Transition Markers in HCVAssociated Hepatocellular Carcinoma: A Multivariate Follow Up Study.上皮-间充质转化标志物在 HCV 相关肝细胞癌中的作用：一项多变量随访研究。
Asian Pac J Cancer Prev. 2022 Mar 1;23(3):839-849. doi: 10.31557/APJCP.2022.23.3.839.
5
COVID-19 Mid-term Impact on Hepatocellular Carcinoma in Patients With Hepatitis C Chronic Infection.COVID-19 对丙型肝炎慢性感染患者肝细胞癌的中期影响。
In Vivo. 2021 Nov-Dec;35(6):3377-3383. doi: 10.21873/invivo.12636.
6
Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents.血清维生素 D、白细胞介素 13 和 microRNA-135a 在埃及 HCV 感染患者接受直接抗病毒药物治疗中对肝癌及治疗失败的作用。
Viruses. 2021 Oct 6;13(10):2008. doi: 10.3390/v13102008.
7
Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma.病毒性肝炎相关肝细胞癌的危险因素与预防
Front Oncol. 2021 Sep 9;11:686962. doi: 10.3389/fonc.2021.686962. eCollection 2021.
8
HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development.丙型肝炎病毒蛋白调节宿主细胞微小RNA表达，促进丙型肝炎发病机制及肝细胞癌发展。
Cancers (Basel). 2021 May 19;13(10):2485. doi: 10.3390/cancers13102485.
本文引用的文献
1
Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗丙型肝炎病毒感染患者的疾病进展。
Clin Gastroenterol Hepatol. 2020 Oct;18(11):2554-2563.e3. doi: 10.1016/j.cgh.2020.02.044. Epub 2020 Feb 28.
2
Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals.血清微小RNA是直接作用抗病毒药物治疗后早期肝细胞癌检测的有前景的生物标志物。
Cancers (Basel). 2019 Nov 11;11(11):1773. doi: 10.3390/cancers11111773.
3
Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response.肝脂肪变性是慢性丙型肝炎患者持续病毒学应答后不良结局的主要预测因素。
J Viral Hepat. 2019 Nov;26(11):1257-1265. doi: 10.1111/jvh.13167. Epub 2019 Jul 17.
4
Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response.血清神经酰胺预测慢性丙型肝炎肝硬化患者持续病毒学应答后的肝细胞癌。
Liver Int. 2019 Nov;39(11):2174-2183. doi: 10.1111/liv.14178. Epub 2019 Jul 3.
5
HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.HCV 诱导的与肝癌风险相关的表观遗传变化在持续病毒学应答后仍然存在。
Gastroenterology. 2019 Jun;156(8):2313-2329.e7. doi: 10.1053/j.gastro.2019.02.038. Epub 2019 Mar 2.
6
Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection.慢性丙型肝炎病毒感染直接抗病毒治疗期间固有免疫应答的动态变化。
J Viral Hepat. 2019 Mar;26(3):362-372. doi: 10.1111/jvh.13041. Epub 2019 Jan 3.
7
Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection.丙型肝炎病毒感染患者接受直接抗病毒治疗后肝细胞癌发生的预测因素。
Hepatol Res. 2019 Feb;49(2):136-146. doi: 10.1111/hepr.13278. Epub 2018 Nov 20.
8
Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus.紫藤凝集素阳性的Mac-2结合蛋白可预测丙型肝炎病毒直接抗病毒药物实现持续病毒学应答后肝细胞癌的早期发生。
Hepatol Res. 2018 Dec;48(13):1131-1139. doi: 10.1111/hepr.13233. Epub 2018 Aug 23.
9
Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals.肝血管生成素-2 是丙型肝炎病毒直接作用抗病毒药物后新发或复发性肝细胞癌的关键预测因子。
Hepatology. 2018 Sep;68(3):1010-1024. doi: 10.1002/hep.29911.
10
Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals.血清细胞因子水平与 HCV 感染患者接受直接作用抗病毒药物治疗后发生肝细胞癌的发展相关。
Gastroenterology. 2018 Feb;154(3):515-517.e3. doi: 10.1053/j.gastro.2017.10.035. Epub 2017 Nov 2.
Zotero 插件